The changing prognosis of melanoma

被引：14

作者：

Buzaid A.C. ^{[1
]}

Anderson C.M. ^{[2
]}

机构：

[1] Oncology Center, Hospital Sirio-Libanês, 01308-050, São Paulo, SP

[2] Department of Medicine, Hematology/Oncology, Ellis Fischel Cancer Center, University of Missouri Health Sciences Center, 65203, Columbia, MO

来源：

Current Oncology Reports | 2000年 / 2卷 / 4期

关键词：

Melanoma; Clin Oncol; Sentinel Node Biopsy; Cutaneous Melanoma; Wide Local Excision;

D O I：

10.1007/s11912-000-0025-9

中图分类号：

学科分类号：

摘要：

Cutaneous melanoma is a significant and increasing clinical problem. Knowing accurately the prognosis in a given patient is critical for treatment decisions and for optimal patient education. In this article we discuss the most current information regarding prognostic factors in early-stage and advanced malignant melanoma. Tumor thickness and ulceration are the most important predictors for primary melanoma. Number of positive lymph nodes is the most powerful predictor for stage III patients, and sites of disease and lactase dehydrogenase levels are the most useful predictors in metastatic disease.

引用

页码：322 / 328

页数：6

共 31 条

[1]

Breslow A, Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma, Ann Surg, 172, pp. 902-908, (1970)

[2]

Buzaid A, Ross M, Balch C, Critical analysis of the current American Joint Committee on Cancer Staging system for cutaneous melanoma and proposal of a new staging system, J Clin Oncol, 15, pp. 1039-1051, (1997)

[3]

Vollmer R, Malignant melanoma: a multivariate analysis of prognostic factors, Pathol Annu, 24, pp. 383-407, (1989)

[4]

Buttner P, Garbe C, Bertz J, Primary cutaneous melanoma: optimized cutoff points of tumor thickness and importance of Clark’s level for prognostic classification, Cancer, 75, pp. 2499-2506, (1995)

[5]

Carlson J, Dickersin G, Sober A, Barnhill R, Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 28 cases, Cancer, 75, pp. 478-494, (1995)

[6]

Quinn M, Crotty K, Thompson J, Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients, Cancer, 83, pp. 1128-1135, (1998)

[7]

Clark W, Elder D, DuPont GI, Model predicting survival in stage I melanoma based on tumor progression, J Natl Cancer Inst, 81, pp. 1893-1904, (1989)

[8]

Massi D, Franchi A, Borgognoni L, Thin cutaneous malignant melanoma (<1.5 mm): identification of risk factors indicative of progression, Cancer, 85, pp. 1067-1076, (1999)

[9]

Morton D, Wen D, Wong J, Technical details of intraoperative lymphatic mapping for early stage melanoma, Arch Surg, 127, pp. 392-399, (1992)

[10]

Gershenwald J, Thompson W, Mansfield P, Multi-institutional lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients, J Clin Oncol, 17, pp. 976-983, (1999)

← 1 2 3 4 →